What do systematic reviews say?

Cannabidiol vs placebo

• Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  Moderate

Cannabidiol vs placebo

• Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 53 participants
  Moderate

Cannabidiol vs placebo

Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).

• Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
  RR 1.28 [1.05, 1.56]
  1 study · 60 participants
  Moderate

Cannabidiol vs placebo

Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).

• Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
  RR 0.15 [0.01, 2.83]
  1 study · 60 participants
  Low

Cannabidiol vs placebo

Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).

• Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
  RR 2.14 [0.83, 5.51]
  1 study · 60 participants
  Low

Cannabis cigarettes vs placebo

The review found no eligible studies for this question.

• Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cannabis cigarettes vs placebo

The review found no eligible studies for this question.

• Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical disinfectants vs standard care or other active treatment (antibiotic or other disinfectant)

Topical disinfectants showed no clear difference in peritonitis (number of patients with one or more episodes) compared with standard care or other active treatment (antibiotic or other… (low certainty).

• Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.83 [0.65, 1.06]
  6 studies · 853 participants
  Low

Topical disinfectants vs standard care or other active treatment (antibiotic or other disinfectant)

Topical disinfectants showed no clear difference in exit‐site/tunnel infection (number of patients with one or more… compared with standard care or other active treatment (antibiotic or other… (low certainty).

• Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.74, 1.27]
  7 studies · 913 participants
  Low

Topical disinfectants vs standard care or other active treatment (antibiotic or other disinfectant)

Topical disinfectants showed no clear difference in catheter removal or replacement (number of patients) compared with standard care or other active treatment (antibiotic or other… (low certainty).

• Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.89 [0.57, 1.38]
  6 studies · 792 participants
  Low

Sildenafil vs active control

It is very uncertain whether sildenafil changes all‐cause mortality compared with active control (very low certainty).

• Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
  RR 0.55 [0.05, 5.75]
  1 study · 65 participants
  Very low

Bismuth subsalicylate vs placebo

It is very uncertain whether bismuth subsalicylate changes clinical response compared with placebo (very low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 5.25 [0.94, 1.9]
  1 study · 5 participants
  Very low

Bismuth subsalicylate vs placebo

It is very uncertain whether bismuth subsalicylate changes histological response compared with placebo (very low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 1.33 [0.27, 6.6]
  1 study · 5 participants
  Very low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide may leads to higher clinical response compared with mesalazine (low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 2.03 [1.25, 3.33]
  2 studies · 57 participants
  Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide may leads to higher histological response compared with mesalazine (low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 2.44 [1.13, 5.28]
  2 studies · 39 participants
  Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 0.67 [0.12, 3.59]
  1 study · 42 participants
  Low

Beclometasone vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Beclometasone dipropionate showed no clear difference in clinical response at 8 weeks compared with mesalazine (low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.75, 1.24]
  1 study · 46 participants
  Low

Beclometasone vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

It is very uncertain whether beclometasone dipropionate changes maintenance of clinical response at 12 weeks compared with mesalazine (very low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 1.29 [0.4, 4.18]
  1 study · 46 participants
  Very low

Cognitive didactic therapy vs functional experiential therapy

Cognitive didactic therapy showed no clear difference in independence in ADL Structured interview compared with functional experiential therapy (low certainty).

• Cognitive rehabilitation for adults with traumatic brain injury to improve occupational outcomes 2017 · Cochrane Headline outcomes only
  RR 0.9 [0.75, 1.08]
  1 study · 366 participants
  Low

Hospital‐based cognitive rehabilitation vs home programme

Hospital‐based cognitive rehabilitation showed no clear difference in return to work Return to work status compared with home programme (moderate certainty).

• Cognitive rehabilitation for adults with traumatic brain injury to improve occupational outcomes 2017 · Cochrane Headline outcomes only
  RR 0.95 [0.85, 1.05]
  1 study · 120 participants
  Moderate